Noxopharm Ltd. · ASX:NOX
Noxopharm — Share Café Micro/Small Cap Hidden Gems Webinar (May 2021)
16 slides from Noxopharm's conference presentation, May 13, 2021
Slide 1: Noxopharm to Present to Share Café Hidden Gems Webinar
Noxopharm Limited (ASX:NOX) | ASX Announcement | 13 May 2021 Noxopharm to Present to Share Café Hidden Gems Webinar Sydney 13 May 2021: Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) provides a copy of the presentation to be made by the Company’s CEO and Managing Dire
Slide 2: Forward Looking Statements
Investor, Corporate & Media enquiries: Company Secretary: Prue Kelly David Franks M: 0459 022 445 T: +61 2 8072 1400 E: [email protected] E: [email protected] Forward Looking Statements This announcement may contain forward-looking statements. You can identify these statements by the
Slide 3: Noxopharm Corporate Presentation May 2021
NOXOPHARM CORPORATE PRESENTATION MAY 2021 Discover Dr Graham Kelly Develop CEO and Managing Director NOXOPHARM LIMITED (ASX:NOX) Deliver NOXOPHARM LIMITED 1 PRESENTATION: MAY 2021
Slide 4: Disclaimer
DISCLAIMER This presentation has been prepared by Noxopharm Limited (NOX or the Company). It statements included in this presentation are reasonable, none of the Company, its should not be considered as an offer or invitation to subscribe for, or purchase any Directors or officers can give, or gives
Slide 5: Introduction
INTRODUCTION NOXOPHARM LIMITED 3 PRESENTATION: MAY 2021
Slide 6: Snapshot
SNAPSHOT Noxopharm is building a pipeline of drugs ~10 million Cancer based on a unique 55 million and proprietary technology platform. Annual deaths eg., lung cancer Current focus on globally from treatment of cancer disease and septic shock ~10 million Septic shock Source: World Health Organisatio
Slide 7: Link between Cancer & Septic Shock
LINK BETWEEN CANCER & SEPTIC SHOCK Manipulates the immune system to Cancer avoid immune attack Increases inflammation to Veyonda® enable growth and First in class Both cancer & septic shock involve spread inhibitor of NADH abnormal immune oxidases and and inflammatory tyrosine kinases responses impl
Slide 8: NOX Business Overview
NOX BUSINESS OVERVIEW CANCER CANCER SEPTIC SHOCK Veyonda® Veyonda® Pipeline Establish Establish New class of Veyonda as Veyonda as oncology drugs inhibitor of standard targeting ‘helper’ ‘cytokine storm’ enhancer of support tissues in viral infections common cancer treatments PHARMORAGE Novel family
Slide 9: Veyonda and Cancer
VEYONDA® AND CANCER NOXOPHARM LIMITED 7 PRESENTATION: MAY 2021
Slide 10: Veyonda 4-Pillars Oncology Strategy
VEYONDA® 4-PILLARS ONCOLOGY STRATEGY Aim is to position Veyonda as a first-in-class booster of major cancer treatments IONIC DARRT LuPIN CEP NOXOPHARM LIMITED 8 PRESENTATION: MAY 2021
Slide 11: Veyonda 4-Pillars Oncology Program
VEYONDA® - 4-PILLARS ONCOLOGY PROGRAM CEP program IONIC program DARRT program LuPIN program checkpoint external beam targeted drug chemotherapy inhibitors radiotherapy therapy Approximate global $50 billion $20 billion $7 billion (pred.) $3 billion market size (US$) Four major commercial opportuniti
Slide 12: Veyonda Tumour-Fighting Cold to Hot Effect
VEYONDA® - TUMOUR-FIGHTING COLD TO HOT EFFECT Effectiveness of current anti-cancer therapies believed limited by absence of an effective immune function inside tumours. Veyonda designed to restore this function Majority of human Converting COLD tumours are COLD tumors to HOT means (lacking active th
Slide 13: Veyonda 4-Pillars Oncology Program
VEYONDA® - 4-PILLARS ONCOLOGY PROGRAM CEP program IONIC program DARRT program LuPIN program checkpoint external beam targeted drug chemotherapy inhibitors radiotherapy therapy Clinical evidence Phase 1b/2a trial Phase 1b trial Pre-clinical Phase 1b trial of Veyonda cancer-boosting evidence effects ☑
Slide 14: Veyonda 4-Pillars Oncology Strategy Summary
VEYONDA® 4-PILLARS ONCOLOGY STRATEGY Aim = to position Veyonda as a first-in-class booster of major cancer treatments SUMMARY We are on-track with early proof-of-concept found in late-stage cancers in combination with • chemotherapy (carboplatin) • radiotherapy • targeted drug therapy (radiopharmace
Slide 15: Key Metrics
KEY METRICS (at 12 May 2021) News Flow (next 6 months) Market cap A$145m IONIC-1, DARRT-2 & CEP-2 start patient recruitment Share price A$0.52 COVID-19 clinical trial completion Novel drug pipeline Issued shares 278.9m Pharmorage progressing novel drug development for chronic inflammation and autoim
Slide 16: For Further Information
FOR FURTHER INFORMATION: info@noxopharm Discover www.noxopharm.com Develop @Noxopharm Deliver NOXOPHARM LIMITED 14 PRESENTATION: MAY 2021
Noxopharm — Share Café Micro/Small Cap Hidden Gems Webinar (May 2021) on 6ix